Human SLC7A11 Full-Length Protein（Nanodisc）信息：

Human SLC7A11 Full-Length Protein（Nanodisc）活性信息：

 固定化人源SLC7A11全長(zhǎng)蛋白（納米盤）（產(chǎn)品編號(hào)：PLDP0055）在濃度為5 μg/mL（100 μL/孔）的條件下,，可與抗SLC7A11抗體結(jié)合,，其EC50值為0.6786 ng/mL。

制劑信息:

蛋白背景信息：

 SLC7A11（Solute Carrier Family 7 Member 11,，又名xCT）是溶質(zhì)轉(zhuǎn)運(yùn)第7家族的第11個(gè)成員，屬于胱氨酸/谷氨酸逆向轉(zhuǎn)運(yùn)蛋白,，主要參與氨基酸在質(zhì)膜上的轉(zhuǎn)運(yùn),，來保護(hù)細(xì)胞免受氧化應(yīng)激的損傷,，維持細(xì)胞氧化還原平衡，從而阻止細(xì)胞因脂質(zhì)過氧化而導(dǎo)致的細(xì)胞死亡 [1-3],。

 SLC7A11蛋白在多種惡性腫瘤中過表達(dá),，已經(jīng)被證實(shí)與膠質(zhì)瘤、乳腺癌,、卵巢癌,、肝癌和肺癌等實(shí)體惡性腫瘤的生長(zhǎng)、預(yù)后,、轉(zhuǎn)移和治療密切相關(guān),，為惡性腫瘤新的潛在分子標(biāo)志物和治療靶點(diǎn)[4-5]。然而,，目前 SLC7A11 抑制劑的臨床應(yīng)用受限,，急需進(jìn)一步研究高特異性 SLC7A11 抑制劑用于惡性腫瘤的治療。此外,，SLC7A11蛋白在血液系統(tǒng)惡性腫瘤中的臨床意義及機(jī)制有待于進(jìn)一步研究,，此類研究可能為相關(guān)疾病提供潛在的治療靶點(diǎn)，并為臨床相關(guān)分子標(biāo)志物提供理論基礎(chǔ)及參考,。

 [1] Bassi, Maria, et al. "Identification and characterisation of human xCT that co-expresses, with 4F2 heavy chain, the amino acid transport activity system xc-." Pflügers Archiv 442.2 (2001): 286-296.

 [2] Lin, Wenyu, et al. "SLC7A11/xCT in cancer: biological functions and therapeutic implications." American journal of cancer research 10.10 (2020): 3106.

 [3] Koppula, Pranavi, et al. "Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer." Cancer Communications 38.1 (2018): 1-13.

 [4] Gout PW, Kang YJ, Buckley DJ, et al. Increased cystine uptake capability associated with malignant progression of Nb2 lymphoma cells[J]. Leukemia, 1997, 11(8):1329-1337.

 [5] Gout PW, Buckley AR, Simms CR, et al. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the xc - cystine transporter: a new action for an old drug[J]. Leukemia, 2001, 15(10):1633- 1640.